Clinical trials: Myeloma, Multiple
Multiple Myeloma
Bone Marker Assessment of Multiple Myeloma Patients Treated With Aminobisphosphonates
The purpose of this research study is to define the time a molecule in the participants bones called NTX begins to rise after receiving treatment with bisphosphonates.
- Trial name
- NCT00577642
- Testing
- Zoledronic acid
- Where
- United States
- Volunteers
- 29 people
- Sponsor
- Massachusetts General Hospital
Cancer
Mycophenolate Mofetil (MMF) for Treatment of Chronic Graft-versus-host Disease (GVHD)
RATIONALE: Mycophenolate mofetil added to immunosuppressive treatment regimens may be effective in treating newly diagnosed chronic graft-versus-host disease caused by stem cell transplantation.
- Trial name
- NCT00089141
- Testing
- mycophenolate mofetil
- Where
- 16 sites in United States, Canada
- Volunteers
- 151 people
- Sponsor
- Martin, Paul
Multiple Myeloma
A Survey on NINLARO Risk Management Plan (RMP) Material Utilization Among Pharmacists in Japan
This is a survey among pharmacists who have instructed NINLARO therapy in ixazomib, lenalidomide and dexamethasone (IRD) dosing to patients with relapsed/refractory multiple myeloma (rrMM).
- Trial name
- NCT05882279
- Testing
- No Intervention
- Where
- Japan
- Volunteers
- 330 people
- Sponsor
- Takeda
Hodgkin's Lymphoma, Lymphoid Leukemia
Adoptive Immunotherapy in Relapsed Hematological Malignancy: Early GVHD Prophylaxis
Determine the relapse-free, donor lymphocyte infusion (DLI)-free survival in patients receiving the investigational regimen.This is a randomized phase II clinical trial, comparing two different dosing schedules of mycophenolate…
- Conditions
- Hodgkin's Lymphoma, Lymphoid Leukemia, Lymphoma, Leukemia
- Trial name
- NCT02593123
- Testing
- mycophenolate mofetil, Sargramostim, Filgrastim
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- Virginia Commonwealth University
Multiple Myeloma, Refractory Multiple Myeloma
A Phase II Study of Daratumumab, Clarithromycin, Pomalidomide And Dexamethasone (D-ClaPd) In Multiple Myeloma Patients Previously Exposed to Daratumumab
This is a single-center, non-randomized, phase 2 study in which patients will receive daratumumab (subcutaneous, SC) in combination with clarithromycin/pomalidomide/dexamethasone (D-ClaPd) until progressive disease (PD) or…
- Conditions
- Multiple Myeloma, Refractory Multiple Myeloma, Relapse Multiple Myeloma
- Trial name
- NCT04302324
- Testing
- Daratumumab SC, Clarithromycin, Pomalidomide
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- Weill Medical College of Cornell University
Multiple Myeloma, Multiple Myeloma in Relapse
Pembrolizumab for the Treatment of Relapsed or Refractory Multiple Myeloma After Anti-BCMA CAR-T Therapies
This phase II trial tests whether pembrolizumab works to shrink tumors in patients with multiple myeloma whose cancer has come back (relapsed) or did not respond to previous treatment (refractory) with anti-BCMA CAR-T therapies.
- Conditions
- Multiple Myeloma, Multiple Myeloma in Relapse, Multiple Myeloma, Refractory, Recurrent Plasma Cell Myeloma
- Trial name
- NCT05191472
- Testing
- Pembrolizumab
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- Alfred Chung, MD
Breast Cancer, Colorectal Cancer
Adapting Multiple Behavior Interventions That Effectively Improve Cancer Survivor Health Cancer Survivor Health
This research study will test the efficacy of interactive, web-based interventions that improve diet, physical activity and weight management changes among early stage survivors of breast, prostate, colorectal, endometrial…
- Conditions
- Breast Cancer, Colorectal Cancer, Endometrial Cancer, Kidney Cancer
- Trial name
- AMPLIFY (NCT04000880)
- Testing
- Adapting MultiPLe Behavior Interventions That eFfectively Improve (AMPLIFI) Cancer Survivor Health, Diet-Exercise, Exercise-Diet
- Where
- 2 sites in United States
- Volunteers
- 603 people
- Sponsor
- University of Alabama at Birmingham
Plasma Cell Myeloma
Enhancing Anti--Tetanus Vaccine Response After Autologous Stem Cell Transplantation
This pilot randomized Phase II trial (10 subjects per arm) will compare immune reconstitution following transplantation of an autologous mobilized graft product to reconstitution following transplantation of a mobilized graft…
- Trial name
- NCT02700841
- Testing
- Melphalan, Peripheral Blood Stem Cell Transplantation--CD34 HSCT, Peripheral Blood Stem Cell Transplantation--AHSCT
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- University of Nebraska
Multiple Myeloma
Panobinostat (LBH589): Multiple Myeloma - Autologous Hematopoietic Cell Transplantation (HCT)
The purpose of this study is to learn more about ways to prevent or delay relapse of multiple myeloma (MM). This study will determine the best dosing schedule of LBH589 maintenance therapy as well as the safety (side effects) and…
- Trial name
- NCT02722941
- Testing
- Panobinostat
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Multiple Myeloma
PK Study of Melphalan HCL & Alkeran for Injection of MA Conditioning in MM Patients of Autologous Transplantation
To assess and compare the pharmacokinetics of Melphalan HCL for Injection (Propylene Glycol-Free) versus Alkeran for Injection in multiple myeloma (MM) patients undergoing autologous stem cell transplant (ASCT).
- Trial name
- NCT00925782
- Testing
- Melphalan HCL for Injection (Propylene Glycol-Free)/Alkeran for Injection, Alkeran for Injection/Melphalan HCL for Injection (Propylene Glycol-Free)
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Acrotech Biopharma Inc.
Chronic Leukemia, Hematopoietic and Lymphoid System Neoplasm
Evaluation of a Pain Management Intervention Preparatory to a Future Pragmatic Trial, ASCENT Study
This clinical trial tests how well a pain management intervention preparatory to a future pragmatic trial works in rural dwelling and Hispanic cancer survivors.
- Conditions
- Chronic Leukemia, Hematopoietic and Lymphoid System Neoplasm, Lymphoma, Malignant Solid Neoplasm
- Trial name
- NCT06063603
- Testing
- Acupuncture Therapy, Cancer Pain Management, Cognitive Behavior Therapy
- Where
- 2 sites in United States
- Volunteers
- 51 people
- Sponsor
- Mayo Clinic
Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia
Comparison of Triple GVHD Prophylaxis Regimens for Nonmyeloablative or Reduced Intensity Conditioning Unrelated Mobilized Blood Cell Transplantation
This randomized phase II trial includes a blood stem cell transplant from an unrelated donor to treat blood cancer. The treatment also includes chemotherapy drugs, but in lower doses than conventional (standard) stem cell…
- Conditions
- Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Aggressive Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia
- Trial name
- NCT03246906
- Testing
- Allogeneic Hematopoietic Stem Cell Transplantation, Cyclophosphamide, Cyclosporine
- Where
- United States
- Volunteers
- 150 people
- Sponsor
- Fred Hutchinson Cancer Center
Myelodysplastic Syndrome, Multiple Myeloma
A Trial of Pembrolizumab (MK-3475) in Participants With Blood Cancers (MK-3475-013/KEYNOTE-013)
The purpose of this trial is to evaluate the safety, tolerability, and efficacy of pembrolizumab (MK-3475, KEYTRUDA®) and pembrolizumab in combination with lenalidomide (Cohort 5 only) in hematologic malignancies.
- Conditions
- Myelodysplastic Syndrome, Multiple Myeloma, Hodgkin Lymphoma, Non-Hodgkin Lymphoma
- Trial name
- NCT01953692
- Testing
- Pembrolizumab, Lenalidomide 20 mg, Lenalidomide 25 mg
- Volunteers
- 197 people
- Sponsor
- Merck Sharp & Dohme LLC
Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Lymphoblastic Leukemia in Remission
Ondansetron in Preventing Nausea and Vomiting in Patients Undergoing Stem Cell Transplant
RATIONALE: Ondansetron may help lessen or prevent nausea and vomiting in patients undergoing stem cell transplant. PURPOSE: This phase II trial is studying how well ondansetron works in preventing nausea and vomiting in patients…
- Conditions
- Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Lymphoblastic Leukemia in Remission, Adult Acute Myeloid Leukemia in Remission, Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities
- Trial name
- NCT00795769
- Testing
- ondansetron, survey administration, management of therapy complications
- Where
- United States
- Volunteers
- 49 people
- Sponsor
- Fred Hutchinson Cancer Center
Multiple Myeloma
To Evaluate Safety, Tolerability, and Clinical Activity of the Antibody-drug Conjugate, GSK2857916 Administered in Combination With Lenalidomide Plus Dexamethasone (Arm A), or in Combination With Bortezomib Plus Dexamethasone (Arm B) in Participants With Relapsed/Refractory Multiple Myeloma (RRMM)
This study will evaluate the safety and tolerability profile of belantamab mafodotin when administered in combination with approved regimens of either Lenalidomide Plus Dexamethasone [Len/Dex (Treatment A)] or Bortezomib Plus…
- Trial name
- DREAMM 6 (NCT03544281)
- Testing
- Belantamab mafodotin, Lenalidomide, Dexamethasone
- Where
- 26 sites in United States, Australia and 3 more
- Volunteers
- 153 people
- Sponsor
- GlaxoSmithKline
Multiple Myeloma
Japanese Study of BMS-901608 (Elotuzumab) in Combination With Lenalidomide and Low Dose Dexamethasone
The purpose of this study is to assess the safety and tolerability of Elotuzumab when given in combination with Lenalidomide and low-dose Dexamethasone in subjects with relapsed or refractory multiple myeloma (MM) in Japan.
- Trial name
- NCT01241292
- Testing
- BMS-901608 (Elotuzumab) 10 mg, BMS-901608 (Elotuzumab) 20 mg
- Where
- 3 sites in Japan
- Volunteers
- 7 people
- Sponsor
- Bristol-Myers Squibb
Myeloma, Lymphoma
Evaluation of the Drug Plerixafor in Combination With Chemotherapy and G-CSF for Stem Cell Collection
The purpose of this study is to test whether the addition of the drug plerixafor to treatment with chemotherapy and G-CSF can better activate your bone marrow stem cells to improve the chances of transplant.
- Trial name
- NCT01095757
- Testing
- Plerixafor
- Where
- United States
- Volunteers
- 45 people
- Sponsor
- Emory University
Multiple Myeloma
A Study to Evaluate Daratumumab in Transplant Eligible Participants With Previously Untreated Multiple Myeloma
The purpose of this study is to evaluate if the addition of daratumumab to Bortezomib, Thalidomide and Dexamethasone will increase the stringent complete response rate after consolidation therapy and increase the progression free…
- Trial name
- Cassiopeia (NCT02541383)
- Testing
- Bortezomib (VELCADE), Thalidomide, and Dexamethasone (VTD), Bortezomib, Thalidomide, Dexamethasone (VTD) + daratumumab, Daratumumab
- Where
- 107 sites in Belgium, France and 1 more
- Volunteers
- 1,085 people
- Sponsor
- Intergroupe Francophone du Myelome
Acute Myeloid Leukemia With FLT3/ITD Mutation, Acute Myeloid Leukemia With Gene Mutations
Reduced-Intensity Conditioning Before Donor Stem Cell Transplant in With High-Risk Hematologic Malignancies
This phase II trial studies reduced-intensity conditioning before donor stem cell transplant in treating patients with high-risk hematologic malignancies.
- Conditions
- Acute Myeloid Leukemia With FLT3/ITD Mutation, Acute Myeloid Leukemia With Gene Mutations, Acute Myeloid Leukemia With Inv(3) (q21.3;q26.2); GATA2, MECOM, Acute Myeloid Leukemia With t(6;9) (p23;q34.1); DEK-NUP214
- Trial name
- NCT01760655
- Testing
- Fludarabine phosphate, Busulfan, Total-Body Irradiation
- Where
- United States
- Volunteers
- 62 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Multiple Myeloma
Lenalidomide + Azacitidine for Adaptive Immunotherapy -> Auto SCT in Multiple Myeloma
RATIONALE: Lenalidomide may stimulate the immune system in different ways and stop cancer cells from growing. Drugs used in chemotherapy, such as azacitidine, work in different ways to stop the growth of cancer cells, either by…
- Trial name
- NCT01050790
- Testing
- Azacitidine
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- Virginia Commonwealth University